Epidemiology of Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET) in the European Union (EU)

被引：2
|
作者：
Moulard, Odile [1 ]
Mehta, Jyotsna [2 ]
Olivares, Robert [1 ]
Iqbal, Usman [2 ]
Mesa, Ruben A. [3 ]
机构：
[1] Sanofi, Global Evidence & Value Dev, Chilly Mazarin, France
[2] Sanofi, Global Evidence & Value Dev, Cambridge, MA USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1744.1744
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1744
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (06) : 491 - 497
  • [32] MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia
    Tombak, Anil
    Ay, Ozlem Izci
    Erdal, Mehmet Emin
    Sungur, Mehmet Ali
    Ucar, Mehmet Ali
    Akdeniz, Aydan
    Tiftik, Eyup Naci
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2015, 31 (04) : 416 - 425
  • [33] Increased risks of polycythemia vera (PV), essential Thrombocythemia (ET), and myelofibrosis (MF) among 24577 first-degree relatives of 11039 patients with chronic myeloproliferative disorders (MPD) in sweden.
    Landgren, Ola
    Goldin, Lynn R.
    Kristinsson, Sigurdur Y.
    Samuelsson, Jan
    Bjorkholm, Magnus
    BLOOD, 2007, 110 (11) : 209A - 209A
  • [34] Prevalence of polycythemia vera and essential thrombocythemia
    Ma, Xiaomei
    Gary, K.
    Vanasse, J.
    Selinger, H. Andrew
    Wang, Yun
    Cartmel, Brenda
    BLOOD, 2007, 110 (11) : 240B - 240B
  • [35] A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis
    Verstovsek, Srdan
    Savona, Michael R.
    Mesa, Ruben A.
    Oh, Stephen
    Dong, Hua
    Thai, Dung
    Gotlib, Jason
    BLOOD, 2015, 126 (23)
  • [36] Eryptosis in polycythemia vera and essential thrombocythemia
    Kopka, Pawel
    Blizniewska, Katarzyna
    Sicinska, Paulina
    Duchnowicz, Piotr
    Bukowska, Bozena
    Trelinski, Jacek
    Chojnowski, Krzysztof
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2020, 74 : 69 - 76
  • [37] Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center
    Masarova, Lucia
    Bose, Prithviraj
    Pemmaraju, Naveen
    Daver, Naval
    Cortes, Jorge E.
    Estrov, Zeev
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2017, 130
  • [38] Prevalence of polycythemia vera and essential thrombocythemia
    Ma, Xiaomei
    Vanasse, Gary
    Cartmel, Brenda
    Wang, Yun
    Selinger, H. Andrew
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (05) : 359 - 362
  • [39] A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis
    DeAngelo, Daniel J.
    Tefferi, Ayalew
    Fiskus, Warren
    Mesa, Ruben A.
    Paley, Carole S.
    Wadleigh, Martha
    Snyder, David S.
    Begna, Kebede
    Ondovik, Michael S.
    Rine, Jessica
    Bhalla, Kapil N.
    BLOOD, 2010, 116 (21) : 276 - 277
  • [40] A RUXOLITINIB INDIVIDUAL SUPPLY PROGRAM FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Barosi, G.
    Linardi, C.
    Ben Yehuda, D.
    Henrique Daumas Gabriel, A.
    Perez, J.
    Modi, A.
    Khan, M.
    Zweegman, S.
    Raymakers, R.
    Vianelli, N.
    Pakstyte, S.
    Willenbacher, W.
    Gisslinger, H.
    HAEMATOLOGICA, 2012, 97 : 321 - 321
12345